The dual mechanism of growth hormone regulation
Endocrinology studies show that growth hormone releasing peptides (GHRPs) release growth hormone through mechanisms and points of action that are different from those of growth hormone releasing hormone (GHRH).
Researchers have hypothesized that GHRPs act through a double mechanism, exerting effects at both the pituitary and hypothalamic levels. Because they operate via different pathways, targeting both mechanisms simultaneously allows researchers to manipulate growth hormone secretion more effectively than by using a single signal.
The GHRH pathway and CJC-1295
The first half of the stack targets the growth hormone releasing hormone (GHRH) pathway. Therapeutic use of natural GHRH to enhance growth hormone secretion is limited by its short duration of action. To create a more stable research tool, scientists developed long acting synthetic analogues like CJC-1295. Mechanistic 1
In a human clinical trial involving healthy adults aged 21 to 61, a single subcutaneous administration of CJC-1295 produced sustained, dose dependent increases in mean plasma growth hormone concentrations by 2- to 10-fold for 6 days or more. It also increased mean plasma insulin like growth factor I (IGF-I) concentrations by 1.5- to 3-fold for 9 to 11 days. Human 1
The study demonstrated that the engineered peptide successfully engages the GHRH pathway in people and has an estimated half life of 5.8 to 8.1 days. Human 1
The GHRP pathway and Ipamorelin
The second half of the stack targets the growth hormone releasing peptide (GHRP) receptor. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that stimulates growth hormone release via a GHRP-like receptor. Mechanistic 2
It was developed to improve upon older growth hormone releasing peptides like GHRP-2 and GHRP-6. While those older peptides successfully release growth hormone, administration of both GHRP-6 and GHRP-2 has been shown to result in increased plasma levels of adrenocorticotropic hormone (ACTH) and cortisol. Animal 2
Animal development studies in rats and conscious swine showed that ipamorelin is highly selective. It triggers a strong growth hormone pulse, but it does not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol was evident even at doses more than 200-fold higher than the effective dose for growth hormone release. Animal 2
The mechanics of GHRH and GHRP synergy
The core reason these two classes are stacked is that their combined effect is synergistic rather than simply additive.
This synergy has been proven in human clinical studies using the broader peptide classes. In one study, researchers administered intravenous GHRH (100 micrograms), the peptide GHRP-6 (90 micrograms), and a combination of both to healthy subjects. Human 3
The growth hormone secreted after the combined GHRH plus GHRP-6 treatment was significantly higher than the arithmetic sum of the growth hormone levels produced by both compounds administered separately. Human 3 This synergistic action proves that the most effective way to stimulate secretion is to engage both the GHRH and GHRP pathways at the same time.
Why this specific pair is stacked
The theoretical goal of the stack is to produce a highly amplified pulse of growth hormone. The GHRH analogue provides the sustained synthetic drive, while the GHRP triggers the synergistic release.
The evidence gap for the exact combination
Researchers infer the stack's behaviour entirely from the established synergy of its parent classes and from the individual properties of the two molecules.
Because no human dose has been established for the combination, any dosing protocols discussed in research settings are experimental estimates rather than clinically validated regimens.
For a detailed look at the individual evidence profiles and what is known about their separate effects, see the main CJC-1295 and Ipamorelin review.
CJC-1295 with DAC
Limited evidenceGH secretagogues · 3 cited studies
Human data consist of two small, short, sponsor run pharmacodynamic studies in healthy volunteers measuring only growth hormone and IGF-1; the only other citation is a mouse study, no efficacy trial has ever been completed or published, and the single phase 2 trial was halted and never reported.
UK status. No UK marketing authorisation.
Ipamorelin
Limited evidenceGH secretagogues · 4 cited studies
Human data comprise a single phase 1 pharmacokinetic study and one well conducted phase 2 randomised trial in postoperative ileus that missed its primary endpoint (P=0.15) and all secondary endpoints; the remaining citations are preclinical, and there is no controlled human data of any kind for body composition, recovery or the other uses for which it is marketed.
UK status. No UK marketing authorisation.
UK regulatory and anti doping status
In the UK, neither CJC-1295 nor ipamorelin is approved as a medical treatment. Under the law, 4, any product sold or supplied as a medicine requires a licence from the 5.
Neither peptide has been evaluated for safety or efficacy by the MHRA, and no manufacturer has completed the steps to 6.
In competitive sport, both peptides are strictly prohibited. The World Anti-Doping Agency bans all growth hormone releasing factors, including growth hormone releasing hormone analogues and growth hormone secretagogues, at all times. Athletes subject to testing face severe sanctions for using either compound, whether alone or in a stack. 7
Frequently asked questions
What is GHRH and GHRP synergy?
GHRH and GHRP synergy is a biological effect where combining a growth hormone releasing hormone with a growth hormone releasing peptide produces a growth hormone pulse that is significantly greater than the sum of the two peptides used alone.
Why are CJC-1295 and ipamorelin combined?
CJC-1295 and ipamorelin are combined to take advantage of class synergy. CJC-1295 acts on the growth hormone releasing hormone pathway, while ipamorelin acts on the growth hormone releasing peptide pathway. Engaging both pathways simultaneously produces a much larger growth hormone response than either pathway alone.
Is there human data for the CJC-1295 and ipamorelin stack?
No. While the synergy between their respective peptide classes has been proven in human studies, the specific combination of CJC-1295 and ipamorelin has not been tested in a published human clinical trial. No human dose has been established for the pair.
Are these peptides approved for human use?
No. Neither peptide is approved by the MHRA in the UK. They are experimental compounds and are banned in competitive sport by the World Anti-Doping Agency.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism.PubMed · DOI · View study in BioRx
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.PubMed · DOI · View study in BioRx
- PubMed, PMID 7883854
- Human Medicines Regulations 2012, regulation 46: a medicinal product needs a marketing authorisation to be sold or supplied
- MHRA, the Medicines and Healthcare products Regulatory Agency
- MHRA guidance: apply for a licence to market a medicine in the UK
- WADA Prohibited List
